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1. Introduction 
The mature central nervous system (CNS) is probably the most complex structure known in 
nature.  This fact and the irreversibility of most forms of clinical brain damage are the basis 
for the long-held belief that the adult brain cannot restore itself and cannot be repaired. 
Parkinson’s disease (PD) is a chronic and progressive neurodegenerative disorder 
characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta 
(SNPc) with a concomitant loss of the catecholamine called dopamine (DA), the 
neurotransmitter released at the axon terminals of the SNPc neurons that project to the 
striatum (caudate nucleus and putamen) (Fig.1). 
Historically, the therapy for PD is aimed at reinstalling proper stimulation of the dopamine 
receptors in striatum. The dramatic breakthrough was the introduction of L-DOPA 
treatment in 1969 (Cotzias et al., 1969).  L-DOPA, the precursor of dopamine, passes the 
blood-brain barrier (BBB) and is converted to dopamine, which becomes available for 
dopamine receptors in striatum, thereby improving the balance between excitatory and 
inhibitory influences in this brain region. Together with L-DOPA treatment, dopamine 
reuptake inhibitor, dopaminergic agonists and muscarinic antagonists also have a clinical 
effect. Despite this pharmacologic advance in treatment, there remains no cure for PD. 
Because PD is a neurodegenerative process and long term therapy is necessary, 
development of severe side effects such as dyskinesias (movement disorder), limits the 
usefulness of L-DOPA therapy over time and progressively becomes less effective; 
consequently, patients become more troubled by freezing or akinesias. In addition, L-DOPA 
will not only reach the striatum, but the entire CNS as well as the rest of the body, where it 
can develop unwanted side effects. 
Additionally, surgical treatment is being used to treat people with advanced PD for whom 
drug therapy is no longer sufficient. The more frequently employed techniques are 
thalamotomy, lesion of the internal globus pallidus or subthalamic nucleus and chronic 
implantation of electrodes for deep brain stimulation, amongst others. Even though there is 
a clinical recovery in PD patients after surgical therapy, as seen with pharmacological 
therapy, the progression of the disease cannot be avoided. Hence, the basic principle of 
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neural transplantation for PD is to provide DA from the graft in a stable fashion directly into 
the striatum where the intrinsic dopaminergic system has been degenerated (Fig.1). This 
procedure attracted the attention of the entire scientific community over the past decades. 
In this chapter we will describe the experimental work and clinical trials that provided the 
basis for the development of cell therapy in PD. Afterward, this chapter will depict the 
suitability and the therapeutic potential of stem cells from different origin that could be 
employed for regeneration therapy in human clinical trials. Finally, this chapter will discuss 
the current strategies for the assessment of tissue integration after grafting and our proposal 
of an alternative method for evaluating the effectiveness of the transplants in rodent models 
of PD. 
 
 
 
Fig. 1. Transplant therapy in a rodent model of PD.  Grafted cells are located in the 
denervated striatum of the 6-hydroxydopamine (6-OHDA) lesioned rat. 
2. The experimental approach in animal models of PD: the foundation of 
transplant therapy 
Even though PD is mostly idiopathic, it is well known that loss of a specific and highly 
specialized neuronal subpopulation underlie the process of the disease. The optimal tactic to 
evaluate the benefits and/or drawbacks of different treatments, devoid of using human 
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patients, is to develop an animal model that resembles the pathology observed in PD. To 
this point, animal models of PD are the best method to evaluate the success or failure of 
transplant therapy.  
Section 2 depicts the evolution of transplant research done in animal models. A summary of 
the trials can be found in Table 1. 
2.1 Animal models of PD 
The most commonly used PD model is the 6-OHDA unilateral lesioned rat. 6-OHDA is a 
specific neurotoxin for catecholaminergic neurons; uptake of 6-OHDA by these neurons is 
performed in a similar fashion to that for intrinsic catecholamines (Sachs & Jonsson, 1975). 
Because 6-OHDA is not able to cross the BBB, unilateral direct injection into the substantia 
nigra or into the medial forebrain bundle is sufficient to destroy >95% of the midbrain 
dopaminergic neurons. Unilateral lesioned rats will rotate contralaterally in response to DA 
agonists such as apomorphine, which is the result of the supersensitivity of striatal DA 
receptors in the lesioned side. On the opposite, unilateral lesioned rats will rotate 
ipsilaterally to the lesion in response to amphetamine. Circling behavior can be analyzed by 
gross visual observation, video recording or rotometer.   
Another neurotoxin commonly employed for the development of animal models of PD is 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). This toxin was discovered in young 
drug addicts who used illicit drugs contaminated with meperidine, causing symptoms very 
similar to idiopathic PD (Langston et al., 1983). Sensitivity to MPTP varies considerably 
among animal species.  Non-human primates are most sensitive in a manner similar to 
humans; mice, cats, and dogs are rather sensitive, whereas rats are resistant to MPTP (Kopin 
& Markey, 1988).  
2.2 Fetal substantia nigra transplants 
With the extensive variety of animal models of PD, experimental transplant therapy for PD 
swiftly began in the late 70’s; fetal substantia nigra was the initial choice for transplants, 
since fetal tissue was considered to have lower possibility of rejection from the 
host's immune system than adult cells. 
The firsts fetal substantia nigra experimental transplant performed in a PD model, reported 
a reduction of the motor abnormalities in a unilaterally DA-denervated rat (Björklund & 
Stenevi, 1979; Perlow et al., 1979). Since then, the technique has been improved in several 
ways and established that DA-containing grafts can alleviate some of the symptoms in 
different experimental models of PD, including mice and rats (Aguayo et al., 1984; Annett et 
al., 1994; Brundin et al., 1988; Di Porzio & Zuddas, 1992; Dunnett et al., 1981; Hefti et al., 1985; 
Herman et al., 1991; Zhu et al., 1992).  
Once the first experiments using fetal substantia nigra grafts in rodents were concluded and 
giving preliminary and promising results, the next rational step was to extrapolate these 
experiments to a higher member of the evolutionary chain, the non-human primates. 
Morihisa et al., were the first ones to explore the potential of this therapeutic approach, 
transplanting fetal substantia nigra into the denervated caudate nucleus of the rhesus 
monkey with unilateral lesion of the striatum secondary to 6-OHDA direct administration. 
For their surprise, under the specific conditions of their experiment, fetal substantia nigra 
graft did not survive in either of two animals tested. The complete loss of the transplanted 
dopaminergic graft could be due to an immunologic incompatibility; which placed the 
notion that the brain is an immunologically privileged site under inquiry and questioned the 
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idea that rejection processes would be less severe inside the brain. In order to circumvent 
graft rejection, they employed grafts from autolog adrenal medulla tissue; of particular 
interest is that adrenal medulla tissue from four animals tested did survive (Morihisa et al., 
1984). Even though they did not report improvement after adrenal medullary chromaffin 
transplant, they were the pioneers in the usage of autologous transplants for PD treatment, 
one that took notoriety in the years to come. 
2.3 Sympathetic neuron transplants 
The potential therapeutic value of autologous transplants was also explored using 
sympathetic neurons for cell transplant in PD. Sympathetic ganglion cells mainly release 
noradrenaline whereas a minute amount of DA is also synthesized and secreted by a small 
subpopulation of the ganglion cells (Lyon et al., 1987). With this taken into consideration, 
autologous sympathetic neurons derived from the superior cervical ganglion were grafted 
in animal models of PD, monkey and rat. Tissue pieces of the sympathetic ganglion were 
grown in serum-free medium supplemented with nerve growth factor; short neurites were 
found to emanate from sympathetic ganglion tissue after 6 days in culture. These studies 
have revealed that sympathetic neuron autografts placed in the DA-denervated striatum 
survive and improve motor deficits such as drug induced circling behavior and hypokinetic 
disorders, seen in rodent and non-human primate models of PD (Itakura et al., 1988; Nakao 
et al., 1995). 
2.4 Human retinal pigment epithelial (hRPE) cells transplant 
With the arrival of new and more advanced cell culture procedures, innovative sources were 
available for the acquisition of alternative DA-producing cells. Amongst them, the hRPE cell 
was one of the most promising ones; the study of hRPE cells demonstrated that these cells 
express vesicular monoamine transporter and the D1 receptor. Moreover, hRPE cells secrete 
L-DOPA and small quantities of dopamine. This alternative graft was transplanted in a rat 
and monkey model of PD with significant improvement of circling behavior and motor task, 
respectively. Nevertheless, a thorough depiction of dopaminergic transplanted cell survival 
and function was not provided (Doudet et al., 2004; Subramanian et al., 2002).  
2.5 The dim truth about experimental transplant in animal models of PD 
Regardless of the improvement reported in these animal models of PD after transplant, 
several factors were not taken into account in order to make an adequate evaluation of the 
enhancement produced by the graft. Even though there is evidence of a decrease in circling 
behavior, the survival of DA-producing transplanted neurons is not fully described in many 
of the experiments, and for that reason, a correlation between neuronal graft survival and 
behavior improvement cannot be supported.  
With the purpose of making an un-doubtful conclusion that a functional recovery is clearly 
undergoing, a clear correlation between the extent and location of dopaminergic re-
innervation within the striatum and recovery of dopaminergic function should be done. The 
remission of circling behavior may relate to the fact that DA receptors on the denervated 
side are supersensitive and/or that striatum is normally supplied with a far greater 
innervation than is needed for minimal maintenance of function. It is also possible that a 
low number of neurons and terminals may increase their synthesis and turnover of DA to 
help compensate for the deficit. 
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Cell Source Donor Recipient Result 
Time 
period
TH neuron 
count Reference 
(after transplant) 
Fetal 19 days Nigra Rat 
6-OHDA 
unilateral 
lesion Rat 
Decrease in 33% of 
ipsilateral rotation 
(amphetamine) 
3.5 
months
300 neurons 
Björklund & 
Stenevi, 1979 
Fetal Nigra Rat 
6-OHDA 
unilateral 
lesion Rat 
Decrease in 70% of 
contralateral rotation 
(apomorphine) 
4 
weeks
NA 
Perlow et al., 
1979 
Fetal 19 days Nigra Rat 
6-OHDA 
bilateral lesion 
Rat 
Decrease in 50% of 
spontaneous akinesia 
20 days NA 
Dunnett et al., 
1981 
Fetal 16-17 days Nigra Rat 
6-OHDA 
unilateral 
lesion Rat 
Augmentation of DA 
fiber density 
10 
months
NA 
Aguayo et al., 
1984 
Adrenal medulla 
autografts 
 
Rhesus 
macaque 
(non-
human 
primate) 
6-OHDA 
unilateral 
lesion 
Rhesus 
macaque 
NA 
8 
months
150 
cathecolamine 
neurons 
Morihisa et 
al., 1984 
PC12 cells (rat adrenal 
medulla 
pheochromocytoma) 
Rat PC12 
cell culture
6-OHDA 
unilateral 
lesion Rat 
Decrease in 27% of 
ipsilateral rotation 
(amphetamine) 
2 
weeks
NA 
Hefti et al., 
1985 
Superior cervical 
ganglia autografts 
Rhesus 
macaque 
(non-
human 
primate) 
MPTP lesion 
Rhesus 
macaque 
Increase of 60% of 
homovanillic acid 
content in cerebrospinal 
fluid. 
3 
months
NA 
Itakura et al., 
1988 
Fetal 6.5-8 weeks Nigra Human 
6-OHDA 
unilateral 
lesion Rat  
Decrease in 94% of 
ipsilateral rotation 
(amphetamine) 
19 
weeks
1, 600 neurons 
Brundin et 
al., 1988 
Fetal 3 weeks Nigra Pig 
6-OHDA 
unilateral 
lesion Rat  
Abolishment of circling 
behavior 
(amphetamine) 
17 
weeks
Up to 12, 000 
neurons 
Huffaker et 
al., 1989 
Fetal 14 days Nigra Rat 
6-OHDA 
unilateral 
lesion Rat 
Decrease in 50% of 
contralateral rotation 
(apomorphine) 
9 
months
3, 400 neurons 
Herman et al., 
1991 
Fetal 12-13 days Nigra Mouse 
MPTP bilateral 
lesion 
Mouse 
NA 
4 
months
2, 600 neurons 
Di Porzio & 
Zuddas, 1992 
Fetal 14 days Nigra 
expressing 
PKCβ1 cDNA (second 
messenger) 
Rat 
6-OHDA 
unilateral 
lesion Rat 
Decrease in 64% of 
ipsilateral rotation 
(amphetamine) 
8 
weeks
NA 
Zhu et al., 
1992 
Fetal 13-16 days Nigra Rat 
6-OHDA 
unilateral 
lesion Rat 
Decrease in 70% of 
contralateral rotation. 
(apomorphine) 
3 
months
NA 
Chung et al., 
1993 
Fetal 74 days Nigra 
Marmoset
(non-
human 
primate) 
6-OHDA 
unilateral 
lesion 
Marmoset 
Ipsilateral/contralateral 
rotations per minute 
ratio of 0.63 vs 5.15 of 
control lesion 
6 
months
1, 800 neurons 
Annett et al., 
1994 
Superior cervical 
ganglia 
(4-week-old culture) 
Rat 
6-OHDA 
unilateral 
lesion Rat 
Decrease in 40% of 
contralateral rotation 
(apomorphine) 
4 
weeks
NA 
Nakao et al., 
1995. 
Fetal 14 days Nigra 
mixed with cultured 
bFGF-producing cells
Rat 
6-OHDA 
unilateral 
lesion Rat 
Total reversal of 
ipsilateral rotation 
(amphetamine) 
8 
weeks
2, 800 neurons 
 
Takayama et 
al., 1995 
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Cell Source Donor Recipient Result 
Time 
period
TH neuron 
count Reference 
(after transplant) 
Engineered grafts 
Fetal 17 weeks retinal 
pigment epithelial 
cells attached to 
microcarriers 
Human 
6-OHDA 
unilateral 
lesion Rat 
Decrease in 50% of 
contralateral rotation 
(apomorphine) 
12 
weeks
NA 
Subramanian 
et al., 2002 
Fetal retinal pigment 
epithelial cells 
attached to 
microcarriers 
Human 
MPTP lesion 
Rhesus 
macaque 
Improvement of 38% in 
motor tasks 
(personalized scale) 
8 
weeks
NA 
Doudet et al., 
2004 
Table 1. Cell transplant therapy in animal models of PD. 
In spite of the methodological scarcity, these investigations gave the stepping stone towards 
a clinical approach in PD transplantation and supported the idea that it could be 
extrapolated to human clinical trials.   
3. Transplant therapy in PD patients: A leap forward to a potential successful 
treatment 
Transplantation of dopaminergic cells into the denervated striatum is an experimental 
approach that was brought to practice to overcome the disadvantages of medications used 
in the treatment of PD in an attempt to provide the brain with an unlimited source of DA 
synthesized by the grafted cells. On section 3 we depict the clinical trials that have been 
taking place until nowadays (Table 2). 
The results of the first human trials were published in 1980’s. More than 30 years ago, the 
major difficulty for performing a transplant was the shortage of dopaminergic cells suitable 
for transplant and cell-based manipulation techniques were not sophisticated enough at that 
time. The most logical selection was to employ autologus dopaminergic tissue. Several of 
the technical and ethical problems, and probably all of the immunologic difficulties, would 
be solved if catecholamine-producing cells from the patient’s own body were used; this 
reasoning led two independent groups (Backlund et al., 1985; Drucker-Colín et al., 1988) to 
investigate if adult adrenal medullary chromaffin cells were able to function as an 
alternative DA source for transplant. Because the systemic administration of L-DOPA or DA 
agonist has been successfully applied in the treatment of PD, the logical inference was to 
expect that adrenal medullary chromaffin cells might act as a chronic pump for delivering 
DA into the denervated striatum of PD patients. 
The first attempt to use autologus medullary chromaffin cell transplant in PD patients was 
done in Sweden (Backlund et al., 1985), though, the clinical improvement was over a period 
of one week and one of the patients developed a resistance to L-DOPA treatment.  
The first report of significant improvement of symptoms in PD patients after autologous 
medullary chromaffin cell transplant was done by our (Drucker-Colín) group in México 
(Drucker-Colin et al., 1988; Madrazo, 1987, 1988). Our team chose a microsurgical 
transcortical intraventricular approach and implanted autologous adrenal medulla directly 
into the unilateral caudate nucleus. Although the grafts were unilateral, the improvement 
was bilateral and symmetric. The direct contact with the caudate nucleus (without the use of 
a stainless-steel tissue holder that the Swedish group used), exposure to cerebrospinal fluid, 
and the shorter interval between adrenal dissection and transplantation almost certainly 
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made the difference. However, there were significant risks and disadvantages associated 
with autologous adrenal transplants; surgical time in a double operation is considered 
perilous for a PD patient (since most of them are over 60 years) and DA producing cells 
obtained from adrenal medulla might be not sufficient to compensate the neural DA deficit. 
These trials were a breakthrough result in the context of transplant therapy in 
neurodegenerative diseases; the notion that peripheral tissue would be able to survive and 
integrate within the host’s CNS as well as to induce clinical improvement was not 
considered to be possible before these studies. 
Given the promissory results obtained using adrenal chromaffin cells, which showed 
variability and technical difficulties; tissue from fetal substantia nigra became to be 
considered a better option as source of DA cells. Madrazo and Drucker-Colín performed the 
first transplant of fetal substantia nigra using tissue from cadaveric consent donation 
(Madrazo et al., 1988). The two transplanted patients showed an improvement of the UPDRS 
score at 8 weeks post-surgery. 
Some years later, in another attempt to improve autolog transplantation of adrenal 
medullary chromaffin cells, our group took advantage that cultured adrenal chromaffin cells 
differentiate into neurons in a higher rate when they are stimulated by a low frequency 
magnetic field (Drucker-Colín et al., 1999). This study proved that adult differentiated 
adrenal chromaffin cells can be successfully transplanted into the caudate nucleus of a 
patient with PD and substantially mitigate the clinical symptoms and reduce the intake of L-
DOPA medication (see reference video of pre and post-transplanted stages of the surgically 
treated patient). Postoperative clinical assessments revealed a significant amelioration of 
visuospatial deficits and a progressive fading of rigidity and akynesia, as well as an 
improvement in memory tasks; furthermore, a decrease in approximately 70% of L-DOPA 
intake to ameliorate parkinsonian symptoms was reported.  
In spite of the political controversy involving this pioneer studies, the clinical improvement 
obtained in some patients set off the interest of transplant therapy in PD patients around the 
world (Deacon et al., 1997; Freed 1990, 2001; Hirsch et al., 1990; Itakura et al., 1997; Kordower 
1995, 1996; Lindvall et al., 1990; Peterson et al., 1989; Sawle et al., 1992; Watts et al., 2003) (See 
table 2).  
However, the employment of human fetal dopaminergic neurons as a DA source for 
transplant is a complicated approach, due to its availability, which is imposed by ethical 
affairs; for this reason, they have been only employed in some human cases (Freed et al., 
1990; Hauser et al., 1999; Kordower et al., 1995; Lindvall, et al., 1990; Madrazo et al., 1988; 
Mendez et al., 2008; Sawle et al., 1992).  
All these initial trials were performed as “open label” (no placebo group as a control), which 
arose the debate regarding the inclusion of a control placebo group, which is envisaged in 
general as unethical. 
Freed’s group published in 2001 the first double-blind placebo trials using embryonic tissue. 
Their results were considered disappointing by some researchers and promising by others 
(Dunnet et al., 2001; Isacson et al., 2001). The controversy is based in the modest recovery 
observed in the grafted patients compared with the sham group; moreover, the serious 
dyskinetic side effects observed after several years of transplantation, places this procedure 
under a doubtful perception of acceptability. However, the fact they found improvement in 
subjects younger than 60 years, leads to consider better methodologically controlled 
approaches.  
One of the disadvantages in employing this cell source (fetal nigral tissue) is the variability 
of the results; improvements of parkinsonian symptoms occur in patients who received the 
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largest amounts of fetal mesencephalic tissue (Hauser et al., 1999; Sawle et al., 1992), whereas 
in other cases, the transplanted cells did not survive for more than a few months and the 
patients usually return to preoperative state (Goetz et al., 1991; Hirsch et al., 1990). 
Additionally, to maintain the fetal tissue viable after transplantation, long-term 
immunosuppressive treatment is needed. Nonetheless, without a doubt the major limiting 
factor of this approach is the difficulty in obtaining a sufficient amount of human viable fetal 
tissue. 
Dejectedly, as has been observed in those studies, there are some patients that clearly 
demonstrate improvement and others that do not show any recovery; however, it is still not 
possible to unravel this mystery of selectivity. Whitin the possible mechanisms accounting 
for these changes, there is patient age, transplant technique, cell graft source and as the most 
probable candidate the immune system; which remains the most formidable barrier to 
transplantation as a routine medical treatment (Freed et al., 2004). The immune system has 
developed elaborate and effective mechanisms to combat foreign agents and we are now in 
pursuit of elucidating them.   
The successes of human to human organ transplantation, coupled with severe limitations in 
the availability of human organs, propelled research into the use of non-human organs in 
the 1990’s. The domesticated pig was the preferred donor at the time. In an audacious 
attempt to replace fetal tissue, surgery to transplant brain tissue from pig fetuses into the 
caudate-putamen of individuals diagnosed with PD was performed. They reported a clinical 
improvement of rigidity in a period of 7 months and that autoimmune processes did not 
become established in the patients (Deacon et al., 1997). Unfortunately, safety and efficacy 
have not yet been clearly demonstrated, and information is still preliminary to warrant this 
therapy. Current opinion is that the risk of transfer of a significant infectious microorganism 
from the pig to the human recipient of a xenograft is small and ethically acceptable if the 
transplant will be highly beneficial to the host. However, pig specific pathogens are 
considered to be of potential risk, thus, limiting the use of pig xenografts. Clinical 
xenotransplantation is becoming feasible and attractive as a routine therapy, nonetheless, 
some attention should be set on this matter. 
In another attempt to evade the host immune response after transplantation, human retinal 
pigment epithelial (hRPE) cells were taken into consideration. As mentioned previously, 
experimental studies suggested that RPE cells were a suitable cell type to serve as a potential 
enduring source of L-DOPA for implantation into the striatum of animal models of PD 
(Subramanian et al., 2002). These implants ameliorated the motor deficits in rodent and non-
human primate models of PD and immune suppression was not required even when 
transplants were made from one species to another (Doudet et al., 2004; Subramanian et al., 
2002).  
Those results were taken into account in a novel tissue engineering strategy; hRPE cells 
were attached to gelatin microcarriers (spheramineTM) and transplanted into the putamen 
contralateral to the more symptomatic side of patients with Parkinson disease (Watts et al., 
2003). They reported an average improvement of 48% in motor score 12 months after 
implantation evaluated through the Unified Parkinsons’s Disease Rating Scale (UPDRS) 
with the patient in the “off” state, which was sustained for 24 months. Improvement was 
also observed in activities of daily living, quality of life, and motor fluctuations. 
However, in a more recent work, a post-mortem study of a patient enrolled in a similar 
clinical trial reported that only 118 cells from the transplant endured (estimated 0.036% 
survival) and that clinical improvement was not observed (Farag et al., 2009). This 
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engineered tissue approach is still an emerging therapy alternative for PD and the existing 
body of literature is still inadequate to allow conclusions regarding this procedure. 
Concerns related to small sample sizes and a limited number of controlled trials are joined 
with a wide array of methodological issues with the procedure itself. We have no doubt that 
better procedures will arrive alongside the advances in tissue development. 
The leading inquiry raised by transplant therapy hitherto is the variability in functional 
recovery either in animal models and human patients. In human studies, this unevenness is 
not only seen between different trials, but also within groups of PD patients transplanted in 
the same assay. In order to attend such matters, a comprehensive clinical trial must be done, 
one that includes a meticulous analysis of patient selection (e.g., age, level of PD), 
knowledge of the number of DA neurons transplanted, type of surgery, follow up of the 
patient before surgery, monitoring of the clinical improvement after grafting, analysis of cell 
survival and neuron functionality. A successful cell therapy must settle advantages over 
current treatments for lessening motor symptoms in PD patients. Cell replacement should 
provide long-lasting, major improvements of mobility and no manifestation of dyskinesias 
without the need of further therapeutic interventions, an uneasy task that most likely will 
not be achieved by using solid fetal ventral midbrain grafts. This is suggested in the recent 
report from Mendez (Mendez et al., 2008), who transplanted fetal ventral midbrain as 
cellular suspension. The analysis did not reveal development of diskynesias in the 
transplanted PD subjects in a period spanning from 9 to 14 years; moreover, the postmortem 
analysis of the transplanted patients’ brains did not show any sign of degeneration (alpha 
synunclein, ubiquitin), and only a minimum of microglial reaction from the host was found. 
In contrast, in the two double blind placebo trials, where solid pieces of fetal midbrain tissue 
were used, severe microglial reaction was found and diskynesias were also observed (Freed 
et al., 2001; Olanow et al., 2003). Mendez’s results supports a new “hope” in medical 
treatment for PD patients based in stem cell tissue procedures, after the setback given by the 
report from Kordower of transplant analysis following 14 years after the procedure 
(Kordower et al., 2008), in which the postmortem tissue revealed that the grafted cells in the 
striatum were affected by a neurodegenerative mechanism, suggesting that the 
neurodegenerative process was not exclusive of the SNPc. Taken together, the present 
observations suggest that the methodological procedures and not the cell source, are directly 
involved in the limited success of transplant therapy that employs solid portion of fetal 
ventral tissue. 
Currently, there are various ongoing stem cell based clinical trials registered by the National 
Institutes of Health (NIH): (http://www.clinicaltrials.gov/ct2/results?term=transplant 
+parkinson), and new assessments are being developed by the Transeuro consortium (Allan 
et al., 2010) (http://www.transeuro.org.uk/index.html). The European group coordinated 
by Dr. Roger Barker is planning highly controlled studies in the near future (2012). 
Interestingly, the cells to be employed in these trials will be obtained from the midbrain of 
human fetuses, the same tissue we used the first time more than 3 decades ago. Again, as in 
past, the idea still creates controversy between those who concur with such methods and 
those who are unfavorable to it due to the limited success percentage (Holden, 2009).  
We expect that the new trails should provide better motor recovery to the ones observed in 
previous assays. Even though behavioral improvement is seen in experimental transplant 
trials, going from 30% to total reversal of circling behavior (Tables 1 and 3), the motor 
symptoms observed in grafted human subjects when analyzed by UPDRS do not surpass 
60% of clinical improvement (Table 2 and Dunnet et al., 2001). 
www.intechopen.com
 
 Stem Cells in Clinic and Research 
 
410 
Cell Source Donor 
Implant 
Zone 
Result 
Time 
period 
TH 
neuron 
count 
Reference 
(after transplant) 
Autologous adrenal 
medullary tissue 
Human 
Striatum 
(Putamen) 
Improvement of 
rigidity 
1 week NA 
Backlund et al., 
1985 
Autologous adrenal 
medullary tissue 
Human 
Lateral 
Ventricle 
Disappearance of 
rigidity and 
akinesia 
5 
months 
NA 
Madrazo et al., 
1987 
Autologous adrenal 
medullary tissue 
Human 
Striatum 
(Caudate) 
Decrease in 50% 
of L-DOPA dose 
1 year NA 
Drucker-Colín 
et al., 1988 
Autologous adrenal 
medullary tissue/fetal 
13 weeks substantia 
nigra tissue 
Human 
Lateral 
Ventricle 
Disappearance of 
rigidity and 
akinesia. 
Decrease in 70% 
of L-DOPA dose 
2 years NA 
Madrazo et al., 
1988 
Autologous adrenal 
medullary tissue 
Human 
Striatum 
(Putamen) 
Improvement of 
rigidity 
2 
weeks 
Necrotic 
tissue 
Peterson et al., 
1989 
Autologous adrenal 
medullary tissue 
Human 
Striatum 
(Caudate) 
None 
4 
months 
Necrotic 
tissue 
Hirsch et al., 
1990 
Fetal 45-55 days Nigra 
tissue 
Human 
Striatum 
(Caudate 
and 
Putamen) 
Improvement of 
Hoehn –Yahr 
scale from 3.71 to 
2.5 
4 years N.A. Freed et al., 1990 
Fetal 8-9 weeks Nigra 
tissue 
Human 
Striatum 
(Caudate) 
Increase in 130% 
of [18F)-DOPA 
intake in PET 
scan. 
Increase of  
L-DOPA 
effectiveness 
from 2 to 14 
hours 
5 
months 
NA 
Lindvall et al., 
1990 
Autologous adrenal 
medullary tissue 
Human 
Striatum 
(Caudate) 
Clinical 
improvements of 
19% in UPDRS 
score 
2 years NA Goetz et al., 1991 
Autologous adrenal 
medullary tissue 
Human 
Striatum 
(Caudate) 
Decrease in 60% 
of L-DOPA dose 
18 
months 
NA 
López-Lozano et 
al., 1991 
Fetal 8-9 months 
Nigra tissue 
Human 
Striatum 
(Putamen) 
Increase in 200% 
of [18F)-DOPA 
intake. 
1 year NA Sawle et al., 1992 
Fetal 6.5-9 weeks 
Nigra tissue 
Human 
Striatum 
(Putamen) 
Improvement of 
UPDRS from 78 
to 49.5 
18 
months 
210, 000 
neurons 
Kordower et al., 
1995/1997 
Superior cervical 
ganglia autografts 
(stellate ganglion) 
Human 
Striatum 
(Putamen) 
Reduction of 33% 
in the time taken 
to perform motor 
task. 
No changes in 
UPDRS score 
3 years NA 
Itakura et al., 
1997 
Fetal 9 weeks Nigra 
tissue 
Pig 
Striatum 
(Caudate 
and 
Putamen) 
Improvement of 
rigidity 
7 
months 
NA 
Deacon et al., 
1997 
Adrenal medullary 
tissue differentiated 
to DA cells in 60Hz 
magnetic field 
Human 
Striatum 
(Caudate) 
Decrease in 70% 
of L-DOPA dose 
1 
month 
NA 
Drucker-Colín 
et al., 1999 
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Cell Source Donor 
Implant 
Zone 
Result 
Time 
period 
TH 
neuron 
count 
Reference 
(after transplant) 
Fetal 6-9 weeks Nigra 
tissue 
Human 
Substantia 
Nigra Pairs 
compacta 
Clinical 
improvements of 
32% in UPDRS 
score 
20 
months 
80, 000 
neurons 
Hauser et al., 
1999 
Fetal Nigra tissue Human 
Striatum 
(Putamen) 
Increase in 40% 
of [18F)-DOPA 
intake in PET 
scan. 
Clinical 
improvements of 
30% in UPDRS 
score. 
1 year 
30, 000 
neurons 
Freed et al., 2001 
Fetal Nigra tissue Human 
Striatum 
(Putamen) 
Clinical 
improvements of 
15% in UPDRS 
score 
2 years NA 
Olanow et al., 
2003 
Suspended fetal 
ventral midbrain cells 
from 6-10 weeks 
Human 
Striatum 
(Putamen) 
Increase in 185% 
of [18F)-DOPA 
intake in PET 
scan. 
Clinical 
improvements of 
60% in UPDRS 
score 
1 year NA 
Mendez et al., 
2008 
Adult neural stem 
cells 
grown as 
neurospheres 
Human 
Striatum 
(Putamen) 
Increase in 30% 
of [18F)-dopa 
intake in PET 
scan. 
Clinical 
improvements of 
80% in UPDRS 
score 
1 year NA 
Lévesque et al., 
2009 
Autologous bone 
marrow-derived 
mesenchymal stem 
cells 
Human 
Sublateral 
ventricular 
zone 
Clinical 
improvements of 
22% in UPDRS 
score 
3 years NA 
Venkataramana 
et al., 2010 
Engineered grafts 
Retinal Pigment 
Epithelial cells 
attached to 
microcarriers 
Human 
Striatum 
(Putamen) 
Clinical 
improvements of 
48% in UPDRS 
score 
1 year NA Watts et al., 2003 
Retinal Pigment 
Epithelial cells 
attached to 
microcarriers 
Human 
Striatum 
(Putamen) 
None 
6 
months 
118 cells Farag et al., 2009 
Table 2. Cell and stem cell transplant therapy in patients with PD. 
4. Stem cell transplantation: Is it the idyllic approach? 
Early research gazed at ventral mesencephalic fetal dopaminergic tissue for transplantation 
in animal models of PD and PD patients with partial success. Nonetheless, while fetal 
primary tissue showed promise, the widespread clinical application of this approach is 
considered limited due to the matter of rejection and low cell survival. The search for 
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alternative sources able to circumvent at least some of the problems inherent to fetal tissue is 
actually undergoing. 
Since the advent of stem cells, they have been proposed as potential candidates to generate 
dopaminergic mesencephalic neurons and replace the cell loss that takes place in PD. 
Stem cells are of an undifferentiated nature and possess an extend capacity to proliferate, as 
well they are capable to endow cells with the same sort of undifferentiated state. These cells 
are sorted in accordance to their intrinsic capacity to generate different cellular types, ability 
that diminishes throughout embryonic development.  
They are considered totipotent when they are able to originate any kind of embryonic or 
extra-embryonic cell (few days embryo) (Thomson & Odorico, 2000). Further in embryonic 
development, in the blastocyst stage, cells of the inner cell mass (ICM) have the potential to 
contribute to the three embryonic germinal layers, ectoderm, mesoderm and endoderm, and 
they are classified as pluripotent. Finally, when the embryo evolves to the gastrula stage, the 
ICM cells have already differentiated and compromised to a specific lineage, based on the 
elapsed time and location within the embryo. These cells are multipotent and they are 
present in the embryo as well as in the adult organism; an example is the neural stem cells 
(NSC) discussed below.  
We should classify stem cells in three broad groups: Adult neural stem cells (neural stem 
cells and mesenchymal), embryonic stem (ES) cells and the recently obtained induced 
pluripotent stem (iPS) cells. All of them have been considered in greater or lesser degree 
accordingly to their specific characteristics as a potential source of dopaminergic cells. With 
this wide diversity of cells available for transplant, the question directly arising is, “is there 
an idyllic stem cell to be employed as source of dopaminergic neurons?” said it in other 
way, “is there a cell capable of long-term survival, steady release of DA, integration into the 
host brain and therefore induce functional benefits without side effects?” In this section we 
will describe the properties and capacity of stem cells from different origin to become 
dopaminergic neurons, with the purpose of elucidating that question. Additionally, we will 
describe the results of the first stem cell transplant experiments performed in animal models 
of PD and the few trials implemented in humans. 
4.1 Adult neural stem cells  
Several studies indicated the existence of dividing cells in the CNS (Altman, 1969) but the 
discovery and isolation of a subtype of multipotent cells, the NSC, in specific regions of the 
mice adult brain (Reynolds & Weiss, 1992) and later in the human brain (Eriksson et al., 
1998) were the events that clearly revealed that the adult CNS posses an inherent plastic 
capability. This instigated the relentless pursue to replace the cellular loss that takes place in 
the CNS after injury or neurodegenerative diseases.  
NSC are self-renewing progenitors specified to give rise only nervous tissue-specific cell 
types, neurons, glia and oligodendroglia (Reynolds and Weiss, 1996). In adult rodent brain, 
the SVZ and the dentate gyrus of the hippocampus contain NSC population with permanent 
capacity of proliferation (Doetsch et al., 1999; Gage, 2000). These brain areas with potential to 
generate new neurons are defined as neurogenic niches. The advantage of containing an 
adult source of stem cells is the possibility of avoiding the use of human fetal tissue and 
embryonic derived stem cells for replacement therapy in neurodegenerative diseases. 
4.1.1 NSC from adult subventricular zone (SVZ) 
Neural stem cells from the SVZ move in chain migration along the rostral migratory stream 
(RMS) and differentiate into periglomerular interneurons at the olfactory bulb throughout 
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the rat lifespan (Doestch et al., 1999). The functional relevance of permanent replacement of 
periglomerular neurons in the rodent brain is attributed to the olfactory adjustment to odor 
changes in the environment.  
Noteworthy, stem cells in the SVZ are able to respond to adverse damage in the brain. An 
increase in proliferation is observed under traumatic conditions such as acute stroke 
(Arvidsson et al., 2002; Parent et al., 2002) or in chronic stroke after being stimulated by 
transforming growth factor alpha (TGFa) (Guerra et al., 2009). Conversely, in animal models 
of PD, decreased proliferation of the progenitors in the SVZ takes place (Hoglinger et al., 
2004). Interestingly, a simultaneous increase of Paired box gene 6 (Pax6) dopaminergic 
interneurons in the periglomerular layer is also occurring (Winner et al., 2006). The same 
increase of TH+ cells is observed in the olfactory bulb of postmortem tissue in PD patients 
(Huisman et al., 2004). 
The reasons to consider the adult multipotent progenitors of the SVZ as an option to 
regenerate the dopaminergic population in the affected striatum of PD patients are their 
commitment to differentiate into dopaminergic neurons in the olfactory bulb and that they 
remain responsive to different signals.  
However, it is well known that different set of transcription factors determine the correct 
dopaminergic fate in the olfactory bulb and SNPc. In the olfactory bulb, transcription factors 
such as the ETS transcription factor Er81 (Er81), Pax6 and Distal-less homeobox 2 (Dlx2), 
regulate the terminal differentiation of periglomerular dopaminergic neurons (Brill et al., 
2008; Cave and Baker 2009; Hack et al., 2005; Kohwi et al., 2005). Instead, the initial 
specification of dopaminergic mesencephalic neurons from the SNPc is regulated by the 
LIM homeobox transcription factor 1 (Lmx1a) and the homeobox transcription factor 1 
(Msx1) (Andersson et al., 2006). This evidence suggests that the neuroblasts arising from the 
SVZ do not develop into A9 dopaminergic neurons, the cells mainly affected in PD (German 
et al., 1992). Additionally, when NSC are expanded in culture as floating cellular aggregates 
in the neurospheres assay they mainly generate glial cells (Storch et al., 2004). Together, 
these results on animal models suggest that adult NSC arising from the SVZ should not be 
an optimal selection for cell therapy in PD. 
4.1.2 Neural stem cells-fetal derived transplants. 
Different protocols in vitro have been developed to generate dopaminergic neurons from 
NSC (for review see Deirborg et al., 2008). In spite the expansion process of NSC, it decreases 
their potential to differentiate into dopaminergic neurons (Ptak et al., 1995); in rats, it was 
demonstrated that fetal ventral mesencephalic (VM) precursor cells have the potential to 
proliferate and differentiate into dopaminergic neurons in culture when stimulated by the 
growth factor FGF-2 (Studer et al., 1998). An important fact involving the use of the 
expanded fetal neural stem cells is the low survival observed after grafting the lesioned 
striatum (around 3-5%), therefore, the improvement of behavioral deficits is not great 
compared to the one obtained with primary fetal cells (not amplified)  (Brundin et al., 1988). 
Even thought fetal neural stem cells are not the most adequate source for transplant, they 
could be considered a better option than NSC from the SVZ. 
4.1.3 Neural stem cells-adult derived transplant 
NSC from adult tissue have been employed in a relevant clinical trial, neural stem cell-
derived neurons were isolated from cortical and subcortical tissue and expanded in vitro for 
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several months. Nine months after harvesting, autologous cell suspensions containing 
differentiated dopaminergic and GABAergic neurons were microinjected unilaterally in a 
patient with advanced Parkinson’s disease. Over the next 3 years, the overall UPDRS 
improved by 80%. However, at five years post-operatively, clinical motor scores returned to 
baseline (Table 2) (Lévesque et al., 2009).   
Even though this result is not the most promising one, it laid the foundation for the 
development of autologous neural stem cell based therapy in PD patients and pointed out 
that this source represents another option for cell replacement therapy, avoiding the 
employment of embryonic tissue.  
4.1.4 Mesenchymal stem cells (MSCs) 
Efforts in employing non-fetal stem cells for transplant therapy in PD are also currently 
undergoing. Venkataramana et al. performed a unilateral transplantation of autologous bone 
marrow-derived mesenchymal stem cells (BM-MSCs). The BM-MSCs were transplanted into 
the sublateral ventricular zone by stereotaxic surgery. The transplanted patients showed a 
clinical improvement of 23% in their UPDRS score. Moreover, a subjective improvement 
was found in symptoms like facial expression, gait, and freezing episodes (Venkataramana 
et al., 2010). These results indicate that this new protocol seems to be safe, and no serious 
adverse events occurred after stem-cell transplantation in PD patients, additionally, no fetal 
tissue was needed to obtain human stem cells. However, more efforts should be done to 
improve these stem cell-based techniques in experimental models of PD before using them 
in PD patients. 
As far as we know, this is the last report of a clinical trial in PD patients. Taking this and all 
of the previous works done for transplant therapy in PD patients, we can state that the 
international quest for the best transplant therapy should not have been taken with such 
haste; a more detailed analysis of graft survival and long term clinical improvement are 
considered necessary. Relevant concerns prevail about methodology aspects, and also about 
the most debated complication of cell therapy in PD, the occurrence of post-operative graft-
induced dyskinesias in the majority of the clinical protocols. 
4.2 Embryonic stem cells: The most promising source of dopaminergic neurons 
The information described above shows that even thought fetal midbrain precursors have 
capacity to proliferate and differentiate into dopaminergic neurons, the efficiency of this 
process in culture is low, therefore, restricting their potential as donor tissue.  ES cells 
instead have the unique ability to self-renew indefinitely while maintaining the potential to 
give rise to all cell types in the human body. These two properties of ES cells make them 
gain a remarkable interest as promising tools for regenerative medicine, specially in PD 
transplant therapy. Another advantage that propelled the use of stem cells is that genetic 
manipulations has became easily practicable in the last few years. 
Nevertheless, currently there are three major aspects limiting the success of stem cell 
therapy; one being the low number of stem cells sources with the potential to differentiate 
into the mesencephalic dopaminergic phenotype; the limited survival of grafted cells 
transplanted in both animal models and humans; and the most important, the danger of 
teratomas.  
In this section, we summarize the different attempts to increase the number of stem cells 
using basically 3 different culture systems (feeder stromal cells, embryoid bodies and neural 
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rossetes) to induce differentiation towards a dopaminergic phenotype. Evaluation of 
survival, integration and function of ES-dopaminergic cells after transplantation in animal 
models of PD is also described. 
4.2.1 Mouse Embryonic stem (mES) cells 
In 2000, Kawasaki et al. performed the first grafted study of mice ES-dopaminergic derived 
cells into the mouse striatum that had been previously treated with 6-OHDA. The system 
used to derivate TH mesencephalic-type neurons consisted in culturing ES cells onto the 
bone marrow stromal cell line PA6, which they identified to have the feature (by unknown 
mechanism) of promoting specific dopaminergic differentiation. The number of TH neurons 
obtained by this co-culture method is significantly higher (~16% of the total cells) to the five 
stages protocol reported in the same year by Lee et  and collaborators (Lee et al., 2000). Two 
weeks after transplantation, 22% of the grafted TH-positive neurons survived and even 
though the improvement of rotational behavior after transplant was not analyzed, they 
confirmed that ES-dopaminergic cells are capable of being transplanted into a parkinsonian 
model and survive, which laid the interest to explore further possibilities for therapeutic 
application (Kawasaki et al., 2000).  
In continuance work, other research groups have been improving culture protocols in order 
to increase the number of dopaminergic neurons to be grafted. In 2002, the first transplant of 
mES cells took place, Kim et al. reported that ~78% of dopaminergic neurons could be 
derived from mES cells in vitro. The highest number of TH cells reported until now was 
promoted by the overexpression of the nuclear receptor related-1 (Nurr1), a transcription 
factor relevant in the induction of mesencephalic precursors into dopamine neurons (Wallen 
et al., 1999). Interestingly, a remarkable behavioral improvement after grafting was 
observed; the transplanted parkinsonian rats presented a total reversal of amphetamine-
induced rotational behavior 8 weeks after transplant (Kim et al., 2002). The behavioral 
enhancement correlates with the evaluated release of dopamine and functional synapses of 
the trasplanted cells. Additionally, no tumor formation was found.  
That same year, Bjorklund et al. followed an opposite transplant approach. The group 
grafted ES cells on embryoid body (EB) stage. It is important to mention that EBs are 
aggregated of cells with spherical shape that differentiate stochastically from ES cells under 
specific in vitro conditions, they have the inherent property of recapitulate embryonic 
development and were developed the first time by Lee in a 5 stage protocol (Lee et al., 2000). 
Rats transplanted with EB presented a decrease in 46% of amphetamine-induced rotation 9 
weeks after transplantation (Bjorklund et al., 2002). The reasoning of the improvement in the 
motor asymmetry is that the ES cell-derived neurons released dopamine in sufficient 
amount when they were stimulated by amphetamine. However, the number of TH+ 
neurons produced after grafting was not studied. They instead analyzed the functional 
activity of ES cells by PET imaging, finding high similarity to that observed in transplanted 
dopaminergic midbrain fetal neurons. Unfortunately, in contrast to the study realized by 
Kim et al., 25% of the animals developed tumors, a result expected given the fact that not all 
of the grafted cells were in a differentiated state. 
To improve the therapeutic potential of ES cells Barberi et al. implemented a faster and 
simpler culture method. Their protocol consisted in the induction of the differentiation of 
mice ES cells into dopaminergic neurons using the feeder stromal cell line (MS5). They 
found that nuclear transfer-derived ES dopaminergic neurons following this protocol and 
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transplantation into the striatum of parkinsonian mice provoked a decrease in 80% of 
circling behavior; additionally, some animals contained up to 40,000 transplanted TH+ 
neurons 8 weeks after transplant (Barberi et al., 2003). 
In another effort to obtain functional DA neurons derived from ES cells but without any 
genetic modification, Rodríguez-Gómez et al. generated CNS progenitor populations from 
mES cells that were later expanded and promoted to differentiate into dopaminergic 
neurons in the presence of mitogen and specific signaling molecules. Mitogen withdrawal 
from the growth medium was done after expressing Engrailed 1 (En1), Paired box gene 2 
(Pax2), and Orthodenticle homeobox 2 (Otx2) specific neuronal transcription factors, hence, 
achieving differentiation (Rodríguez-Gómez et al., 2007). They also described that in the 
grafted animals, PET imaging showed that the number of postsynaptic DA D2 receptors was 
normalized in the host striatum. Additionally, microdialysis in grafted animals displayed 
that dopaminergic transplanted neurons release was induced by depolarization and 
pharmacological stimulants. Their data suggest that ES cell-derived neurons release DA in a 
physiological manner and that reuptake postsynaptic responses remains after implantation. 
On the other hand, to optimize the procedure for generation of mesencephalic dopaminergic 
neurons from ES cells, Jönsson et al. elaborated a protocol to determine the optimal stage of 
development of cells used for grafting. By means of fluorescence-activated cell sorting 
procedures, they isolated DA precursors from mouse ventral mesencephalon in two defined 
stages of differentiation, at 10.5 and 12.5 embryonic days, when the dopaminergic 
mesencephalic neurons are arising. After transplantation into the striatum of 6-OHDA-
lesioned rats, the histological analysis showed that TH-expressing cells poorly survived 
sorting and transplantation; however, this study demonstrated that the differentiation state 
of the progenitors is important. The transplanted neuroblasts originate more TH+ cells 
when obtained from an early state of differentiation (Jönsson et al., 2009). These outcomes 
have inferences for recent efforts to develop well-characterized stem cell-derived 
mesencephalic DA progenitor cell preparations for future cell therapy. 
Even though the 6-OHDA lesioned rat is a great model of PD for analyzing ES cell 
transplant therapy, before considering preliminary transplantation trials in PD patients, 
experiments on non-human primates are quintessential. With this in mind, Takagi et al. 
generated neurospheres composed of neural progenitors from monkey ES cells cultured on 
PA6 stromal feeder cells and transplanted them into the putamen of MPTP lesioned 
monkeys. They reported a significant behavioral recovery and an average survival of 2,100 
TH+ transplanted neurons 14 weeks after transplantation; additionally, PET imaging 
revealed a 50% increase in 18F-fluorodopa uptake. This study demonstrated that the 
transplanted ES cells functioned as DA neurons and alleviated the motor symptoms in a 
parkinsonian non-human primate (Takagi et al., 2005); furthermore, they demonstrated that 
ES cell transplant therapy might be an appropriate treatment alternative to human PD 
patients.  
4.2.2 Human ES cells 
After Thomson isolated stem cells from human embryo (Thomson et al., 1998), the next 
boundary to overcome was to generate neural progenitors derived from human ES (hES) 
cells. In an innovating experiment, undifferentiated hES cells were plated on fresh 
mitotically inactivated feeders and cultured for 8 days to induce neural differentiation, these 
progenitors were transplanted into the striatum of parkinsonian rats. The grafts survived for 
at least 12 weeks, managed to differentiate in vivo to DA neurons and improved circling 
www.intechopen.com
 
Cell Therapy for Parkinson’s Disease:Failure or Success? 
 
417 
behavior with a 45% reduction of amphetamine-induced ipsilateral rotation (Ben-Hur et al., 
2004). Induced dopaminergic differentiation from hES was shortly addressed by other 
groups with different culture approaches but with similar relatively successful outcomes 
(Brederlau et al., 2006; Chiba et al., 2008; Cho et al. 2008; Roy et al., 2006). 
Roy used a combined strategy to improve dopaminergic neuron amounts. Sonic hedgehog 
(Shh) and fibroblast growth factor 8 (FGF-8) were co-cultured with telomerase-
immortalized hES cells derived from human fetal midbrain astrocytes in order induce a 
dopaminergic neuronal fate. After achieving a high number of TH+ cells specific for the 
A9 dopaminergic lineage (colocalizing with the G protein–gated inwardly rectifying K+ 
channel, Girk2), they were transplanted into the striatum of 6-OHDA lesioned 
parkinsonian rats. The authors reported that the dopaminergic implants generated a 
significant, substantial and long-lasting restitution of motor function. Nonetheless, the 
grafts displayed increasing cores of undifferentiated mitotic neuroepithelial cells, which 
can turn tumorigenic (Roy et al., 2006). These data dictate the need for extreme caution in 
developing a clinical application of hES cell-derived grafts, given their potential for 
undifferentiated expansion, yet they also proved that TH+ neurons can be obtained 
and/or induced from a diverse source of cells. 
Chiba et al. followed a different method to improve hES cell transformation to 
phenotypically stable DA neurons. They blocked the effect of the neuronal differentiation 
promoter Noggin by means of the bone morphogenic protein (BMP) antagonist. With this 
strategy they found that BMP inhibitor Noggin increased production of DA neurons from 
hES cells differentiated on PA6 stromal cells. In addition, these DA neurons survived 
transplantation and led to behavioral improvement in parkinsonian rats 4 weeks after 
grafting (Chiba et al., 2008). These neurons derived from hES cells may not be suitable for 
eventual transplantation into PD patients (due to a triple trisomy created by continuous 
passaging), but with this work, they demonstrated that Noggin has a critical role for 
determining midbrain dopaminergic phenotype at an early stage in ES cell differentiation, 
which will be of great value for future research in dopaminergic cell engineering. 
The recent generation of dopaminergic mesencephalic neurons obtained from human ES 
cells by employing spherical neural masses (SNMs), also called neural rossete cells, is 
considered the protocol that allows to yield the higher number of dopaminergic neurons in 
cell culture (roughly 66%) (Cho et al., 2008). SNMs are columnar epitelial structures that 
represent a novel NSC type, distinct and more primitive than those previously characterized 
from other NSC stages (Elkabetz et al., 2008; Pankratz et al., 2007). NSC in neural rossetes 
mimic the neural plate stage and can be directed towards a dopaminergic mesencephalic 
lineage by employing the signaling molecules Shh and FGF-8 (Elkabetz et al., 2008; Cho et al., 
2008). However, whether the fully differentiated DA cells obtained from this novel protocol 
have an ameliorative effect on parkinsonian rodent models or PD patients still remains to be 
determined. Cho and collaborators decided to transplant cells originated from neural 
rossetes in the initial stage of dopaminergic neuronal specification into the lesioned striatum 
of parkinsonian rats in order to avoid a low survival rate. In this specific time point, 
approximately 50% of the cells were TH+ and immunohistochemical analysis demonstrated 
that only 2.7% of the grafted neurons were TH+ 12 weeks after transplantation. Despite this 
low cell number, a significant behavioral recovery was observed in 3 different motor 
behavioral tests. Although this stem cell source is promissory due to the high number of 
yield DA cells without the need of genetic modifications or employment of feeder cells; this 
technique stills needs to circumvent the problem of low survival ratio, which is generally 
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observed when terminal differentiated cells are grafted. Additionally, in order to generate 
an efficient long-term culture (30 to 40 days), experimented handling and dedicated efforts 
are required. These results also point out the necessity of better and rational procedures to 
direct cell specification to a desired phenotype in vitro.  
The bulk of results suggest ES cell transplantation is approaching the point of technical 
practicability toward clinical therapy for PD. hES cell transplantation has the potential to be 
considered one of the most promising therapies for PD treatment; however, this excitement 
is gradually fading as a result of political and ethical concerns. Amongst the limiting 
methodological factors, is the difficulty to maintain normal karyotype and to avoid tumor 
formation. Furthermore, the differentiation rate of ES cells towards a dopaminergic lineage 
is not high enough to obtain sufficient dopaminergic cells for transplantation.  
4.3 Induced pluripotent cells: The most recent breakthrough in stem cells field 
Induced pluripotent (iPS) cells are derived from somatic differentiated cells by 
overexpression of specific transcription factors, which induces cell reprogramming. They are 
fairly similar to ES cells in terms of self-renewal and pluripotency, which provides them 
with the potential to differentiate into any cell type in the organism.  
iPS cells were obtained for the first time in 2006 by Yamanaka´s group; they were acquired 
from embryonic and adult mouse fibroblasts reprogrammed to a pluripotent-like state by 
viral transduction of four transcription factors: Klf4, cMyc, Oct3/4 and Sox2. The obtained 
cells demonstrated to possess typical ES cells properties (Takahashi et al., 2006); however, 
they did not form effective fertile chimeras, meaning that the ability to transmit genotype 
through the germinal line was not achieved, this being one of the most important properties 
that defines a pluripotent cell. This was later rein-vindicated in 2007 in a parallel work by 
Jaenisch´s and Yamanaka´s groups, they successfully reprogrammed fibroblasts and 
obtained viable chimeras (Okita et al., 2007; Wernig et al., 2007); nonetheless, they 
emphasized that the transduction of c-Myc should be avoided in iPSC reprogramming, due 
to its tumorigenic capacity. 
At the end of 2007, and almost simultaneously, Takahashi and Yu were able to manufacture 
iPS cells from human dermal fibroblast. Takahashi enforced the expression of the same 
transcription factors employed in the previous study (Klf4, cMyc, Oct3/4, Sox2); while Yu et 
al., demonstrated that other two transcription factors, Nanog and LIN28 (besides Oct3/4, 
Sox2) were also relevant in cell reprogramming (Takahashi et al., 2007; Yu et al., 2007). One 
year later, iPS cells were derived from human fetal tissue, neonatal and adult somatic cells 
by employing the same combination of genes used by the pioneer team, they also reported 
that c-Myc only increases the efficiency of reprogrammation, but it is not essential for the 
establishment of a pluripotency state, suggesting that c-Myc could be nonessential for 
reprogrammation (Park et al., 2008). Taken together, these results reveal that iPS cells are an 
attractive resource for replacement therapy, given the fact that its use would overcome the 
technical and ethical difficulties of ES cells by avoiding the use of human embryos, 
circumventing transplant rejection and therefore avoiding the use of immune suppressants. 
However, concerns for the transduction of the oncogen c-Myc were still latent and attempts 
to remove it from the transcription factor cocktail were in progress.  
Later in the same year, it was demonstrated that c-Myc is absolutely expendable to obtain 
viable iPS cells, either from mice and human samples (Nakagawa et al., 2008). With the 
removal of this specific proto-oncogen, the possibility of tumor formation was reduced, and 
therefore, research on possible clinical applications achieved important notoriety. 
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iPS cell lines obtained from patients afflicted with different diseases have been developed 
with the purpose of investigating the therapeutic potential of autologous transplants, but 
also to offer an unprecedented opportunity to recapitulate pathological conditions in vitro 
(Gunaseeli et al., 2010; Park et al., 2008). Neurodegenerative diseases are particularly taken 
into consideration, since they are secondary to a relatively selective loss of neurons, for that 
reason, the quest for replacing the neuronal loss of a specific population employing iPS cells 
is currently undergoing in a similar way that occur for ES cells. 
The iPS cells neuronal differentiation in vitro assays have been successful and were 
achieved by employing established ES cell differentiation protocols. The first 
dopaminergic differentiation was obtained from neural precursors derived from mice iPS 
cells. These cells were grafted into the mice fetal encephalon (chimerical brain) and 
revealed a high capacity for migration, differentiation and integration within different 
brain areas. The iPS-derived dopaminergic neurons generated in this study were grafted 
in the 6-OHDA rat model of PD, such transplants improved significantly circling behavior 
stimulated by amphetamine (Wernig et al., 2008). However, it was reported that the 
presence of undifferentiated cells in the graft promoted tumor formation; this fact 
contributed to the idea that obtaining a purified population is essential for a satisfactory 
transplant outcome. 
It has been proved that pluripotent cell production can be obtained from patients suffering 
from other neurodegenerative disease. Dimos et al. developed iPS cells from patients with 
amyotrophic lateral sclerosis (ALS), which was effectively differentiated in vitro to 
motoneurons, the degenerated cells that are accountable for the development of ALS (Dimos 
et al., 2008). This corroborated that iPS cells patient-specified manufacture is a viable option 
and possess certain advantages over ES cells since iPS cells evade the ethical and 
methodological difficulties presented in ES cells production.  
A new study performed in 2009 widened the possibility of inducing patient-specified neural 
differentiation in vitro into iPS cells engineering. Jaenisch´s group managed to generate 
fibroblast-derived iPS cells from 5 idiophatic PD patients, with the advantage that once the 
cellular reprogrammation employing three transcription factors (Oct4, Klf4 y Sox2) was 
achieved, they were able to remove all viral vectors using Cre-recombinase (iPS cells factor-
free). These cells maintained all the properties of a pluripotent cell and were capable to 
induce neuronal differentiation towards a dopaminergic phenotype in vitro; additionally, 
they have the advantages of being a free viral transcription factor cell line and that overall 
gene expression patterns were more similar to ES cells than carrying-factor iPS cells (Soldner 
et al. 2009). 
Different approaches have been developed in order to analyze the latent benefits of human 
iPS cells in animal models of PD. Cai and collaborators employed a commercially available 
iPS cell line, the IMR90 clone 4, to induce its differentiation towards a mesencephalic 
dopaminergic lineage in culture. Once they achieved the dopaminergic phenotype, they 
were transplanted into the striatum of 6-OHDA unilateral lesioned rats. Six weeks after the 
transplant, they analyzed survival and integration of the transplanted cells within the host 
brain. They reported that several transplanted cells survived, but some of them expressed 
nestin and Ki67 which are expressed in dividing cells, such as tumoral cells (Cai et al., 2010). 
This work however, does not allow conclusions regarding physiological effects, since 
behavioral outcome was not analyzed.  
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Later in that year, Hargus et al. employed dopaminergic neurons derived from factor-free 
iPS cells and transplanted them into the striatum of 6-OHDA unilateral lesioned rats; they 
later analyzed development, growth, survival and degeneration in an in vivo longitudinal 
study. They observed a high level of cell survival with no apparent degeneration; they also 
detected axonal outgrowth in different areas, this can be translated to a soaring capacity of 
the adult brain to keep axonal guidance instructions that allow the transplanted cells to 
integrate within the adult brain. In addition, a progressive reduction of motor asymmetry 
(about 70%) was observed in the transplanted animals over a period of sixteen weeks, 50% 
of the transplanted DA neurons were identified as SNPc mesencephalic cells and presence 
of tumoral cells was null (Hargus et al., 2010). However, synaptic function analysis and a 
longer examination of transplant survival still remain to be done. Besides, the improvement 
of motor asymmetry was similar to the one reported in other experimental trials that 
employed different cells, in that aspect, there is no greater advantage of iPS cells over ES 
cells.  
In 2010, reprogramming mice fibroblast directly into a neuronal phenotype directly to a 
pluripotency stage in vitro was achieved. A combination of 3 genes specifically expressed in 
neural tissue, Ascl1, Brn2 y Myt1l, was transduced by means of a lentiviral vector. These 
kind of cells were called induced neurons (iN), since they expressed neural proteins, 
generate action potentials and form functional synapses; most of these cells express an 
excitatory phenotype that was later confirmed by cortical neural markers and only a low 
number of these cells belong to the GABAergic phenotype (Vierbuchen et al., 2010). Yet, it 
still remains to be determined if iN can be derived from fibroblasts obtained from patients 
afflicted with a neurodegenerative disease, and which transcription factors must be 
overexpressed in order to induce different neuronal phenotypes. 
Regardless of all of the possibilities that iPS cells might offer, the uncertainty about the 
latency of tumor formation by being employed in experimental trials still remains. Albeit, 
better methods to induce reprogrammation are currently being developed, but even with 
viral vector removal, this possibility cannot be totally excluded. 
Additionally, recent results demonstrate that production of aberrant methylation sites are 
originated during the epigenomic reprogrammation of iPS cells. Methylation of human iPS 
cells was observed recurrently at different rates throughout the reprogrammation process. 
Furthermore, the variability of the methylated sites is often seen in iPS cell lines, which 
indicates that there are some regions more prone to insufficient or aberrant 
reprogrammation. These methylated sites are categorized as “hotspots” for incorrect 
epigenomic reprogrammation, this alteration is not a simple anomaly exclusive of the 
pluripotent state, it can also be transmitted through iPS cells differentiation (Lister et al., 
2011).  
So far, iPS cells cannot be employed as a feasible resource for cellular replacement therapy 
and further work needs to be developed before a clinical trial could take place; however, 
without a doubt, they possess great potential to be employed as tools for patient-specific 
disease modeling. 
Finally, if we were to choose the type of cell that would bestow the best results after 
transplantation, taking into consideration the information aforementioned; we believe that 
the most promising candidate today is the ES cell. In order to provide this personal opinion, 
we are leaving aside the ethical issues that embrace them, albeit this kind of concerns are of 
the outmost importance, they are out of the scope of this chapter.  
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Cell Source 
In vitro protocol 
for TH cells 
production 
Recipient Result 
Time 
period 
TH neuron 
count Reference 
(after transplant) 
Mouse Embryonic Stem Cells 
mES cells-
derived 
dopamine 
neurons 
ES cultured on 
PA6 stromal cell 
6-OHDA 
unilateral 
lesion Mouse 
N/A 
2 
weeks 
13, 000 
(~22% of the 
original 
graft) 
Kawasaki 
et al., 2000 
mES cells (no 
differentiated) 
Embryoid body 
formation stage 
6-OHDA 
unilateral 
lesion Rat 
Decrease in 46% 
of ipsilateral 
rotation 
(amphetamine) 
9 
weeks 
NA 
Bjorklund 
et al., 2002 
mES cells-
derived 
dopamine 
neurons 
Genetically-
engineered to 
over express 
Nurr1 
 
6-OHDA 
bilateral 
lesion Rat 
 
Total reversal of 
ipsilateral 
rotation 
(amphetamine) 
8 
weeks 
20, 000 
Kim et al., 
2002 
ntES cell-
derived 
dopamine 
neurons 
Nuclear transfer-
derived ES 
(ntES). 
Coculture with 
stromal cells 
6-OHDA 
unilateral 
lesion Mouse 
Decrease in 80% 
of ipsilateral 
rotation 
(amphetamine) 
8 
weeks 
~22,000 
(some 
reaching 
40,000) 
Barberi et 
al., 2003 
mES cells-
derived 
dopamine 
neurons 
Mice transfected 
with GFP 
differentiated 
using 
5 stages protocol 
6-OHDA 
unilateral 
lesion Mouse 
Decrease in 50% 
of ipsilateral 
rotation 
(amphetamine) 
2 
weeks 
NA 
Nishimura 
et al., 2003 
mES cells-
derived 
dopamine 
neurons 
Differentiated 
using 
5 stages protocol 
6-OHDA 
unilateral 
lesion Rat 
Total reversal 
of ipsilateral 
rotation 
(amphetamine) 
Starting at 4 
weeks 
32 
weeks 
 
5, 000 
 
Rodriguez-
Gomez et 
al., 2007 
ntES cell-
derived from 
parkinsonian 
mice 
Nuclear transfer-
derived ES 
(ntES). 
Coculture with 
stromal cells 
6-OHDA 
unilateral 
lesion mouse 
Total reversal 
of ipsilateral 
rotation 
(amphetamine) 
10 
weeks 
Avg 8,784 ± 
4,293 cells in 
the group 
with better 
results 
Tabar et al., 
2008 
Mesencephalic 
DA neurons 
Ngn2-GFP mice 
Pitx3-GFP mice 
Nestin-GFP mice 
Sox2-GFP mice 
6-OHDA 
unilateral 
lesion Rat 
Total reversal 
of ipsilateral 
rotation 
(amphetamine) 
Starting at 3 
weeks 
6 
weeks 
440 
Jönsson et 
al., 2009 
Non-human primates Embryonic Stem Cells (monkey ES cells) 
Non-human 
primates ES 
cells 
Neural 
progenitors 
expanded as 
neurospheres. 
FGF2 addition 
MPTP 
bilateral 
lesion 
Cynomolgus 
monkeys 
Behavioral 
improvement in 
neurological 
score 
14 
weeks 
2, 100 per 
side 
Takagi et 
al., 2005 
Human Embryonic Stem cells 
hES cells 
Culture of hES 
cells enriched 
with neural 
progenitors 
6-OHDA 
unilateral 
lesion Rat 
Decrease in 45% 
of ipsilateral 
rotation 
(amphetamine) 
12 
weeks 
389 
(0.18% of the 
graft) 
Ben-Hur et 
al., 2004 
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Cell Source 
In vitro protocol 
for TH cells 
production 
Recipient Result 
Time 
period 
TH neuron 
count Reference 
(after transplant) 
Decrease in 31% 
of contralateral 
rotation 
(apomorphine) 
hES cells-
derived 
dopamine 
neurons 
Culture on PA6 
cells (stromal 
cells) 
6-OHDA 
unilateral 
lesion Rat 
No 
improvement 
(amphetamine) 
13 
weeks 
10-50 
Brederlau 
et al., 2006 
hES cells-
derived 
dopamine 
neurons 
Cocultured with 
human 
telomerase-
immortalized 
midbrain 
astrocytes 
6-OHDA 
unilateral 
lesion Rat 
Total reversal 
of ipsilateral 
rotation 
(apomorphine) 
Since 6 
weeks 
26,000 per 
mm3 
 
Roy et al., 
2006 
hES cells-
derived 
dopamine 
neurons 
Generation of 
spherical neural 
masses (SNMs) 
(rossetes) 
6-OHDA 
unilateral 
lesion Rat 
Decrease in 
49.43% 
of contralateral 
rotation 
(apomorphine) 
Decrease in 
58.37% 
of ipsilateral 
rotation  
(amphetamine) 
12 
weeks 
10,700 
(2.7% of 
transplanted 
cells) 
Cho et al. 
2008 
Induced Pluripotent Stem cells 
iPS clone O9 
Reprogrammed 
fibroblasts 
(mouse) 
6-OHDA 
unilateral 
lesion Rat 
Decrease in 60% 
of ipsilateral 
rotation 
(amphetamine) 
8 
weeks 
29, 000 
Wernig et 
al., 2008 
iPS cells 
IMR90 clone 4 
Reprogrammed 
fibroblasts 
(human) 
6-OHDA 
unilateral 
lesion Rat 
Decline in 
rotation score 
6 
weeks 
NA 
Cai et al., 
2010 
iPS cells 
excisable virus 
Human PD 
(patients) 
6-OHDA 
unilateral 
lesion Rat 
Decrease in 70% 
of ipsilateral 
rotation 
(amphetamine) 
16 
weeks 
122 neurons 
per mm3 
Hargus et 
al., 2010 
Table 3. Stem cell therapy in animal models of PD. 
5. Evaluating the functional effectiveness of Stem Cell Therapy for PD 
One of the major difficulties in restoring the motor functionality in PD through transplant 
therapy is the correct integration of grafted cells into the nigrostriatal pathway; they are 
required to improve motor symptoms and circumvent the appearance of undesirable side 
effects, such as dyskinesia (Politis et al., 2010). Grafted cells should not only provide a DA 
source for the correct modulation of the basal ganglia, but also be able to integrate the 
nigrostriatal pathway and receive the regulatory input that allows compensatory 
mechanisms, such as feedback regulation. In addition, the complexity of the adult brain and 
the lack of a permissive environment to neuronal regeneration make it particularly 
complicated for even the best non-modified or engineered stem cell to integrate into 
the basal ganglia motor loop. 
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Cell grafts might be able to compensate the loss of modulatory inputs from the SNPc by 
forming local neural circuits within the striatum (Barker et al., 1999; Kreitzer et al., 2008; 
Lindvall et al., 2004). Ideally, these circuits should be capable to modulate basal ganglia 
pathways through interaction with D2 and the D1 dopamine receptors, as well as to be 
subject to feedback regulation in order to prevent variations of DA availability. 
In order to evaluate these neural circuits, the need of joined functional and behavioral tests 
to assess improvement is one of the main objectives. The use of positron emission 
tomography (PET) coupled to magnetic resonance imaging (MRI) techniques has 
diminished the gap between behavioral and functional data.  
5.1 MRI assessments 
Conventional MRI reveals brain structural changes as reductions in volume (atrophy) and 
alterations in water-proton relaxation T1 and T2 signals. Water normally flows along neural 
tracts in the brain. Diffusion-weighted or diffusion tensor MRI can be used to quantify loss 
of anisotropy (directionality) or increase in amplitude of water diffusion in order to 
demonstrate disruption of neural tracts.  
Conventional T1 and T2 weighted MRI show normal nigral structure in idiopathic PD and 
therefore is not diagnostically helpful. Volumetric T1 weighted MRI studies have also failed 
to detect a reduction in nigral volume in PD, possibly because of difficulties in accurately 
defining the border of the SNPc (Geng et al., 2006) and thus it would be the most 
appropriate technique for evaluating the survival of dopamine-derived transplants.  
MRI inversion recovery sequences can be designed to suppress either gray or white matter 
signal. Segmented inversion recovery ratio imaging generates ratio images of gray matter 
and white matter suppressed signal at a voxel level. With the segmented inversion recovery 
ratio approach, PD patients were reported to show a gradient of altered nigral signal that 
was absent in healthy controls (Hutchinson & Raff, 2000). Although the use of gray matter 
and white matter suppressing inversion recovery sequences can detect changes in nigral 
structures in PD, it is a complicated approach to implement and currently not 
sensitive enough to be of diagnostic value in transplant therapy.  
Regardless of the limitations previously mentioned, MRI is a non-invasive, real-time cellular 
imaging modality that has no radiation, and for these reasons, several attempts have been 
made in order to take advantage of these qualities. New MRI techniques currently employ 
magnetic labeling using superparamagnetic iron oxide particles (SPIOs) coupled to stem 
cells transplanted in the rat striatum with the purpose of assessing the survival time of 
transplanted tissue (Berman et al., 2011; Obenaus et al., 2011). Nevertheless, this innovative 
technique is only useful for quantifying cell survival and does not provide data to evaluate 
transplanted cell function.   
5.2 PET assessments 
Terminal dopa decarboxylase activity and dopamine turnover can be assessed using 
radioactive markers such as 6-[18F]-fluoro-L-DOPA (18F-DOPA), which could be helpful for 
the evaluation of PD progression in vivo (Brooks et al., 2008) and graft survival in 
transplanted PD patients (Mendez et al., 2002; Sawle et al., 1992). Early hemiparkinsonian 
patients show a bilateral reduced putamen dopaminergic terminal function. Clinical 
parkinsonism occurs when PD patients have lost 40%–50% of posterior putamen-dopamine 
terminal function (Morrish et al., 1995). Levels of 18F-dopa uptake in the putamen and DAT 
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binding correlate inversely with bradykinesia and rigidity of PD patients, and could be 
valuable for estimation of cell therapy functional recovery.  
However, this type of analysis has limitations; 18F-DOPA is not specific for evaluation of DA 
re-uptake in small animal PET scanning, which is an essential feature for the assessment of 
emergent cell therapy in animal models of PD. Other radiotracers of DAT binding, such as 
[11C]-(+)-α-dihydrotetrabenazine (11C-(+)DTBZ), have better specificity and spatial 
resolution when evaluating animal models of PD (Collantes et al., 2008) and could be used to 
examine the survival of DA neurons.  
Still, in order to correctly evaluate DA release, it is necessary to use radioactively labeled 
dopamine receptor antagonists, such as [11C]-raclopride, which can be displaced from DA 
receptors by DA released from nerve terminals located in situ or exposed to amphetamine 
(Piccini et al., 2000). 11C-raclopride PET is able to indirectly detect synaptic dopamine fluxes 
by monitoring changes in striatal D2 receptor availability (Laruelle, 2000). The higher the 
extracellular dopamine level, the lower the dopamine D2 site availability to the tracer. 
Animal microdialysis studies suggest that a 25% fall in putamen 11C-raclopride uptake after 
amphetamine equates to a 10-fold rise in synaptic dopamine levels (Breier et al., 1997). In PD 
patients, when given L-DOPA treatment, they show a fall in striatal 11C-raclopride binding; 
the response of bradykinesia and rigidity to L-DOPA in PD correlates with the resulting 
increases instriatal dopamine levels detected with 11C-raclopride PET (Pavese et al., 2006).  
By means of 18F-DOPA and [11C]-raclopride PET scans, it has been shown that grafted 
(human embryonic mesencephalic and fetal dopaminergic tissue) cells remain active and 
form connections with neurons residing in the host striatum when transplanted in human 
brains (Mendez et al., 2008; Piccini et al., 1999; Spencer et al., 1992). The major drawback is 
that the spatial resolution achieved with the current available PET scanners (2 × 10−3 m) is 
insufficient to evaluate single cell events, which can only be resolved with 100-fold higher 
resolutions (10–20 μm).   
So far, the information already described shows that current MRI and PET analysis have 
some limitations for a correct cell graft evaluation of survival and integration within the 
host, specifically at the cellular level.  
5.3 Microcircuits on brain slice preparations: the need for functional studies  
It is clear that better protocols for cell replacement therapy would benefit from a better 
understanding of normal basal ganglia circuit functions. One of us (Bargas’ group) designed 
a brain slice preparation in which individual cell activity can be observed and evaluated, 
using calcium-imaging techniques (Carrillo-Reid et al., 2008). When corticostriatal slices are 
loaded with a calcium-sensitive fluorescent dye, it is possible to analyze single-cell activity 
in a widespread area of the striatum. Additionally, it is possible to examine the activity of 
cell clusters that have an associated firing pattern (neural ensembles) and represent 
functional microcircuits within the striatum (Carrillo-Reid, 2008, 2009). Different cells within 
the striatum belong to different ensembles, and there are some cells that belong to most of 
the ensembles present in a given slice. These cells serve as central pattern generators (CPGs), 
which are considered to represent memory traces in the nervous system (Carrillo-Reid, 2008, 
2009; Grillner, 2005, 2006). CPG activity within the striatum might be related to the encoding 
of motor programs that are activated secondary to cortical stimulation.  In this regard, it is 
worth of notice that unstimulated corticostriatal slices mostly show silent cells, with some 
uncoordinated activity.  
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Ensemble activity is triggered by stimulation of cortical fibers or after exposure to 
glutamatergic agonist NMDA. These results suggest the existence of intrinsic microcircuits 
in the striatum, which could be the actual modulators of motor activity in this brain area.  
Thus, it would be necessary to determine if the segregated pathways represented by 
neurons expressing either the D1 or the D2 dopaminergic receptors, belong to distinct 
activity ensembles; this would be of major interest, since deregulation of the D1 receptor 
pathway has been proposed to be responsible for the dyskinesias observed in PD patients 
after prolonged exposure to L-DOPA (Dupre et al., 2008; Santini et al., 2008; Taylor et al., 
2005). Of particular interest would be to demonstrate if there is a difference between 
ensembles in the intact brain and those in the affected striatum of PD patients. 
We propose that the use of this brain slice preparation will allow us to study if transplanted 
dopaminergic cells can integrate into local microcircuits within the striatum, and if 
formation of new modulatory connections could compensate for the loss of the 
dopaminergic input from the SNPc and reestablish control of motor function. 
6. Conclusion 
This chapter highlights that although almost three decades have passed since the Backlund-
Lindvall and Drucker-Colín et al. work was published, transplant therapy for PD is still 
retained as a potential clinical approach; stem cell research is currently providing a more 
adequate source of cells. So far, the large body of evidence appears to validate the use of 
manipulated stem cells in the coming years. 
Although stem cell therapy shows promise, it is still in development, and even with a wide 
range of methods, currently there is no ideal scenario for clinical transplantation and 
perhaps it will not arrive in the near future. ES cell therapy still remains elusive and is 
burdened with social and logistical concerns. In contrast, iPS generation circumvents some 
previous limitations, since it does not require embryonic material. iPS cell technology might 
have a significant impact on regenerative medicine in the near future. 
In order for cell therapy to become a viable option of treatment, a pure source of 
dopaminergic neurons is essential. However, the poor survival of transplanted 
differentiated cells limits transplant therapy; ergo a pure population would not be the best 
option, since cell survival decreases after transplantation. Additionally, the combination 
with other cell populations could also be necessary for a successful transplant, given the fact 
that primary fetal cells that provide behavioral improvement are only ~20% of the total 
implanted cells.  
Finally, it should be particularly noted, that aside of a couple of studies, all report 
incomplete motor improvements. The search for the basis of this result is today still in its 
embryonic stage. As a final point, research with better surgical procedures that provides 
controlled assessments consequently will lead to a more clear understanding of the 
phenomena involved grafting in PD. 
In sum, despite several failures, we believe that cell replacement therapy has a viable future. 
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